Cambrex Corporation (CBM) Position Maintained by Polaris Capital Management LLC

Polaris Capital Management LLC held its position in Cambrex Corporation (NYSE:CBM) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 21,397 shares of the biotechnology company’s stock at the end of the 2nd quarter. Polaris Capital Management LLC owned approximately 0.07% of Cambrex Corporation worth $1,278,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of the company. Stifel Financial Corp increased its holdings in shares of Cambrex Corporation by 0.8% in the 2nd quarter. Stifel Financial Corp now owns 4,580 shares of the biotechnology company’s stock worth $275,000 after buying an additional 37 shares during the last quarter. Dubuque Bank & Trust Co. increased its holdings in shares of Cambrex Corporation by 3.3% in the 2nd quarter. Dubuque Bank & Trust Co. now owns 2,697 shares of the biotechnology company’s stock worth $161,000 after buying an additional 87 shares during the last quarter. YorkBridge Wealth Partners LLC increased its holdings in shares of Cambrex Corporation by 5.2% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,971 shares of the biotechnology company’s stock worth $118,000 after buying an additional 97 shares during the last quarter. Mark Sheptoff Financial Planning LLC increased its holdings in shares of Cambrex Corporation by 2.5% in the 2nd quarter. Mark Sheptoff Financial Planning LLC now owns 4,000 shares of the biotechnology company’s stock worth $239,000 after buying an additional 99 shares during the last quarter. Finally, Louisiana State Employees Retirement System increased its holdings in shares of Cambrex Corporation by 0.8% in the 2nd quarter. Louisiana State Employees Retirement System now owns 13,300 shares of the biotechnology company’s stock worth $795,000 after buying an additional 100 shares during the last quarter.

A number of analysts have recently weighed in on CBM shares. BidaskClub downgraded shares of Cambrex Corporation from a “hold” rating to a “sell” rating in a report on Thursday, August 24th. ValuEngine upgraded shares of Cambrex Corporation from a “hold” rating to a “buy” rating in a report on Tuesday, August 22nd. Finally, Zacks Investment Research downgraded shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. Cambrex Corporation has an average rating of “Hold” and a consensus price target of $65.67.

WARNING: “Cambrex Corporation (CBM) Position Maintained by Polaris Capital Management LLC” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/10/13/cambrex-corporation-cbm-position-maintained-by-polaris-capital-management-llc.html.

Shares of Cambrex Corporation (CBM) traded up 0.75% during trading on Friday, reaching $53.90. 31,056 shares of the company traded hands. The firm has a 50 day moving average of $53.07 and a 200 day moving average of $55.46. The stock has a market capitalization of $1.76 billion, a PE ratio of 19.64 and a beta of 2.28. Cambrex Corporation has a 52 week low of $38.30 and a 52 week high of $62.95.

Cambrex Corporation (NYSE:CBM) last released its quarterly earnings data on Friday, August 4th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.76. Cambrex Corporation had a net margin of 17.70% and a return on equity of 24.25%. The firm had revenue of $134.55 million during the quarter, compared to analysts’ expectations of $136.82 million. During the same period last year, the business earned $0.68 earnings per share. Cambrex Corporation’s revenue was up 13.4% compared to the same quarter last year. On average, equities analysts predict that Cambrex Corporation will post $3.08 EPS for the current year.

In other Cambrex Corporation news, CEO Steven M. Klosk sold 4,000 shares of Cambrex Corporation stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $54.96, for a total transaction of $219,840.00. Following the completion of the sale, the chief executive officer now directly owns 87,328 shares in the company, valued at $4,799,546.88. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Steven M. Klosk sold 12,000 shares of Cambrex Corporation stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $51.53, for a total transaction of $618,360.00. Following the sale, the chief executive officer now owns 95,328 shares of the company’s stock, valued at $4,912,251.84. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 28,000 shares of company stock valued at $1,574,880. 2.48% of the stock is owned by company insiders.

Cambrex Corporation Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corporation (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex Corporation (NYSE:CBM)

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply